Multiple sclerosis journal - experimental, translational and clinical · 2026
Absence of significant hematologic abnormalities in breastfed infants of mothers with multiple sclerosis treated with anti-CD20 therapies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shah Anna, Alvarez Enrique
Аннотация
OBJECTIVES: To assess hematologic abnormalities in breastfed infants of mothers with multiple sclerosis (MS) receiving anti-CD20 therapies.
METHODS: Breastfed infants with maternal anti-CD20 use were identified. Infant blood draws examined B-cell (CD19) and hematological counts.
RESULTS: Nine of 10 identified infants had CD19 percentages in ranges expected for age. One infant had CD19 levels below the 5th percentile but was interpreted by their treating pediatrician as normal for age, with no increase in infections reported.
DISCUSSION: The absence of significant CD19 abnormalities in our cohort may indicate infant hematology safety. This may allow mothers MS to utilize anti-CD20 therapies while breastfeeding.
METHODS: Breastfed infants with maternal anti-CD20 use were identified. Infant blood draws examined B-cell (CD19) and hematological counts.
RESULTS: Nine of 10 identified infants had CD19 percentages in ranges expected for age. One infant had CD19 levels below the 5th percentile but was interpreted by their treating pediatrician as normal for age, with no increase in infections reported.
DISCUSSION: The absence of significant CD19 abnormalities in our cohort may indicate infant hematology safety. This may allow mothers MS to utilize anti-CD20 therapies while breastfeeding.